62%+ while the market is correcting - These stocks are shining as others plunge

Investing.com — November has challenged many investors as familiar mega-cap names have struggled to provide clear direction amid volatile earnings reports and shifting interest rate forecasts. For those watching the major indexes, the month has often felt like a pause, with limited opportunities to capitalize on.

However, investors who look beyond the headlines and focus on undervalued, high-potential stocks are uncovering pockets of notable strength. While broad benchmarks remained rather flat, select companies are quietly moving higher, rewarding those who acted early.

This is precisely the kind of market environment that our InvestingPro members have been navigating successfully. For less than $8 a month as part of our limited-time only Early Bird sale, they receive an AI-picked monthly list of promising opportunities, including standout performers that have delivered impressive returns in recent weeks.

*InvestingPro members can click here to jump straight to the full list of November value picks.

Still not a member? Then this is your final chance to subscribe at up to 55 % off and secure access to the top picks for November.

• App users can subscribe here
• Web users can subscribe here

These are some of our winners in November:

• Haemonetics (NYSE: HAE): +50.21% in November ALONE
• Holley (NYSE: HLLY): +28.57% in November ALONE
• Seers Technology (KOSDAQ: A458870): +62.50% in November ALONE
• Sampoerna Agro (IDX: SGRO): +46.27% in November ALONE

Here’s why Haemonetics has emerged as one of the market’s most compelling opportunities:

Haemonetics isn’t just part of one strategy. It appears in three of our top ProPicks strategies — Top Value Stocks, Mid-Cap Movers, and Healthcare Heroes — reflecting a strong alignment between its business prospects and the qualities investors look for in undervalued companies.

This is not simply a one-time spike driven by a fortunate earnings report. These are real-world, live results rooted in fundamentals our AI flagged months ago.

Across the past several months, ProPicks AI has already identified multiple major winners across value, healthcare, and mid-cap categories — and Haemonetics is simply the latest example of how solid fundamentals combined with attractive valuation and growing momentum can translate into impressive returns.

So if you missed this 50.21% November surge, don’t worry. What matters now is making sure you’re positioned for the next one.

You can NOW use our Early Bird Sale and get up to 55% off.

• App users can subscribe here
• Web users can subscribe here

But why was Haemonetics added to three strategies in the first place?

Haemonetics checked every box our machine-learning engine evaluates — valuation, growth, profitability strength, analyst sentiment, and margin expansion — all pointing to a severely mispriced opportunity.

Here’s the exact rationale our AI flagged on September 1:

1. Deep Undervaluation With Surprisingly Strong Margins

• Trading at just 56% of its 52-week high at the time of selection
• Forward P/E of 14.9 and an exceptionally low PEG ratio of 0.34
• 58.8% gross margin and 19.4% operating margin, both best-in-class
• EBITDA +23.6% YoY, showing healthy underlying growth
• Q1 FY2026 EPS beat by 8.9%, revenue beat by 6.2%

2. Mispricing vs Fair Value

• September price: $53.28
• Analyst fair value: $78
• InvestingPro fair value: $76
• Citi upgrade to Buy with a $90 price target shortly after, signaling more than 60% upside from the time our AI flagged it

3. Core Business Strength

• Plasma business performing exceptionally well with 29% organic growth
• Management focused heavily on margin expansion and profitability
• Temporary headwinds in interventional tech were not structural — and the AI recognized that

This combination of high margins, undervaluation, earnings beats, and a clear path to recovery is exactly what investors want but rarely find at the right time, and those who recognized it early have been rewarded with substantial gains.

But how does the AI behind these picks actually work?

At the start of each month, the AI refreshes every strategy with up to 20 new stock picks, analyzing more than 150 investor-grade financial models built on over 15 years of global market data. It identifies where risk and reward align best — removing underperformers, keeping promising names, and adding fresh opportunities.

Each strategy uses equal weighting across all selected stocks, creating a transparent and consistent way to track results. The goal is not just to find winners, but also to know when to move on from the ones that stop performing.

Check out the 12-year outperformance of Tech Titans over the S&P 500 below:

This means a $100K principal in our strategy would have turned into an eye-popping $2,649,600.

Now is the perfect time to subscribe to InvestingPro and get up to 55% off during our Early Bird Sale.

Disclaimer: Prices mentioned in articles are accurate at the time of publication. We regularly test different offers for our members, which may vary by region.